WHC is still in active development. Read this to understand our approach.
depiction of DQCKKXVULJGBQN-UHFFFAOYSA-N.svg
isomerdesign

17-(Cyclopropylmethy...

Check on isomerdesign

pubchem

Naltrexone

Check on pubchem

drugmap

Naltrexone

Check on drugmap

wiki

Naltrexone

Check on wiki

Data

InChI: InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2

Synonyms: naltrexone,UM-792, Naltrexone depot (injectable suspension), elbion,NALTREXONE [ORANGE BOOK],5S6W795CQM, Vivitrex,NALTREXONE [HSDB],Naltrexone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material,DSSTox_RID_81532, Naltrexone depot (injectable suspension), DrugAbuse Sciences,Vivitrex,NALTREXONE COMPONENT OF CONTRAVE, XR-NTX,Naltrexone [USAN:INN:BAN],Prestwick0_000116, PTI-901,PDSP2_000847,Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5.alpha.)-,N-Cyclopropylmethylnoroxymorphone,(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one,MFCD00242996,Vivitrol,NALTREXONE [MART.],BCP07022, Naltrel,EN-1639A [AS HYDROCHLORIDE],BRN 3596648,NALTREXONE [MI],Naltrexonum,NCGC00024427-04,(-)-Naltrexone,C07253, Opioid antagonists (irritable bowel syndrome), Pain Therapeutics,CAS-16590-41-3,16590-41-3,(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one,(1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one,(4R,4As,7aR)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one, Naltrexone (once-monthly controlled-release, Medisorb), Alkermes,Naltrexone base anhydrous,PTI-555,cyclopropylmethyl(dihydroxy)[?]one,ZINC1773, IBS therapy, Pain Therapeutics,NCGC00024427-05,HSDB 6750,DSSTox_CID_26313,(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride,AB00174152_17,NSC-758439, Naltrexone (polymer microcapsule depot, opioid addiction/alcohol dependency), Biotek, Naltrexone (sustained release), DAS,17-(Cyclopropylmethyl)-3,14-dihydroxy-4,5α-epoxymorphinan-6-one,NALTREXONE [USAN],17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one,4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0~1,13~.0~5,17~.0~7,18~]octadeca-7(18),8,10-trien-14-one,cid_5485201,NCGC00024427-03,(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-bis(oxidanyl)-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride,Naltrexone (USAN/INN),Naltrexonum [INN-Latin],(-)naltrexone,CCRIS 3506,17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one,CHEMBL19019,Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5alpha)-,EINECS 240-649-9,NALTREXONE [WHO-DD],Prestwick2_000116,Naltrexona [INN-Spanish], Naltrexone (transdermal, alcohol/opioid dependence), Syntropharma, Naltrexone (low-dose), Pain Therapeutics,AB00174152-14,BIDD:GT0405,SPBio_002071,BPBio1_000146,BRD-K88172511-003-21-1,BSPBio_000132, Naltrexone (sustained release), elbion,(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one,ReVia,NCGC00162274-02,17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxmorphinan-6-one, (5.alpha.)-,Tox21_112007_1,Celupan,SCHEMBL34681,DSSTox_GSID_46313,BDBM50000787,NALTREXONE [USP-RS],D05113,BDBM60212,N-Cyclopropylmethyl-14-hydroxydihydromorphinone,NALTREXONE [VANDF], Irritable bowel syndrome therapy, Pain Therapeutics,US9107954, naltrexone,Prestwick3_000116,BRD-K88172511-310-03-8,Depotrex,Naltrexona,UNII-5S6W795CQM,Nemexin,EN-1639A FREE BASE,DTXSID4046313,SMP1_000206,Tox21_112007,AKOS015994596,GTPL1639,CS-0880,HMS2089O11,Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy-,HY-76711,HS-0002,CHEBI:7465,Prestwick1_000116,EX-A4863,EN300-19748946,Vivitrol (TN),AC-36726,(5α)-17-(Cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-one, Naltrexone Depot,(4R,4aS,7aR,12bS)-3-(Cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinolin-7(7aH)-one,NSC 758439,DB00704,Q409587, Vivitrol,AR-270/43507956,NALTREXONE [INN],3,14-dihydroxy-17-(cyclopropylmethyl)-4,5alpha-epoxymorphinan-6-one

Estimated data

Solubility: -3.122 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 57.7% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.